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Robert S. Stern1,2 and Annemieke Huibregtse1,3
It has been hypothesized that severe psoriasis is an independent risk factor for cardiovascular disease (CVD).
We prospectively studied patients with severe psoriasis treated with psoralens and ultraviolet-A therapy (PUVA)
who enrolled in a cohort study in 1975–1976. From 1977 to 2005, 617 of the 1,376 patients (45%) died. Compared
with the general population, cohort death rates were significantly higher than expected (standard mortality ratio
(SMR)¼ 1.1, 95% confidence interval (CI)¼ 1.02–1.20). The number of deaths due to CVD (SMR¼ 1.02, 95%
CI¼ 0.9–1.6) was nearly identical to the expected number. Deaths due to liver disease were significantly elevated
(SMR¼ 4.04, 95% CI¼ 2.76–5.70). Patients with exceptionally severe psoriasis at entry (442% body surface
area (BSA)) had a significantly increased risk of death compared with less severely affected cohort members
(all-cause hazard ratio (HR)¼ 1.42, 95% CI¼ 1.18–1.69) as well as for deaths because of causes other than cancer
or CVD (multivariate HR 1.56, 95% CI¼ 1.14–2.13). Only patients with exceptionally severe psoriasis had an
increased mortality risk compared with both the general population and other cohort members with less
extensive but still severe psoriasis. These increases were not significant for CVD. Our data do not support the
hypothesis that severe psoriasis is an independent risk factor for CVD. However, exceptionally severe psoriasis
is associated with increased all-cause mortality.
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INTRODUCTION
Psoriasis is a common, chronic skin disease affectingB2% of
white adults. Less than 5% of those affected report as much as
10% of body surface area (BSA) affected (Stern et al., 2004;
Kurd and Gelfand, 2008). Studies in specialized populations
have found an association of psoriasis, especially severe
psoriasis, with an increased risk of cardiovascular disease
(CVD) (Gelfand et al., 2006, 2007; Ludwig et al., 2007;
Shapiro et al., 2007; Gerdes et al., 2008; Kimball et al.,
2008a, b). These findings are largely based on studies of
specialized populations or administrative databases with
severity defined according to therapies utilized rather than
an objective severity metric.
These findings are the primary basis for the hypothesis that
psoriasis is an independent risk factor for CVD, most likely as
a result of inflammation (Sterry et al., 2007; Fridewald et al.,
2008; Spa¨h, 2008; Kimball et al., 2008a, b). A secondary
hypothesis is that systemic anti-inflammatory immunologic
therapies for cutaneous psoriasis might also reduce cardio-
vascular morbidity and mortality (Prodanovich et al.,
2005; Gelfand et al., 2006, 2007; Sterry et al., 2007;
Fridewald et al., 2008; Spa¨h, 2008; Kimball et al.,
2008a, b). However, recent studies in European populations
suggest that psoriasis is unlikely to be a substantial
independent risk factor for CVD (Brauchli et al., 2009;
Wakkee et al., 2010).
In a 30-year prospective study of patients with severe
psoriasis, we determined cause-specific mortality, tested the
hypothesis that excess in mortality among patients with
severe psoriasis is greater for CVD than that due to other
causes, and examined the relation of mortality risk with the
extent of psoriasis.
RESULTS
Since 1 January 1977, the 1,376 cohort patients have been
studied prospectively for a total of 30,817 person-years. Data
collected from direct contact with patients, their physicians,
and relatives span 26,285 (85%) person-years. Information
from the National Death Index (NDI) comprises an additional
4,532 (15%) person-years of follow-up. Death certificates
were sought for all reported deaths.
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In 1977, the patients’ mean age was 46 (SD±15). A total of
15% reported fair or poor health; 92% had at least 10% of BSA
involved with psoriasis at entry. Nearly all had used systemic
therapy or phototherapies other than psoralens and ultraviolet-A
therapy (PUVA) or had been hospitalized for psoriasis.
Population and risk factors
Table 1 provides the distribution of patient characteristics,
including risk factors for CVD determined from health
histories, laboratory, and medical examinations performed
at entry into the clinical trial (1975–1976) or at the first PUVA
follow-up study interview (1977). Using a standardized form
and method, dermatologists assessed BSA involved with
psoriasis before first PUVA treatment (1975–1976).
Table 2 provides the distribution of levels of exposures to
smoking and psoriasis therapies that varied over the course of
the study. For each year, the patient’s cumulative exposure
was compared with that of all other cohort patients to
determine that patient’s relative level of exposure compared
with the mean level for surviving cohort members in that
year. Each patient’s category for each year was used in the
analysis for that year.
Deaths overall
We documented 617 deaths compared with 560 expected
(standard mortality ratio (SMR)¼1.1, 95% confidence inter-
val (CI)¼ 1.02–1.20). Table 3 presents the observed and
expected deaths and 95% CIs for all-cause mortality and
major causes of death. As detailed in Supplementary Table S1
online, except for liver-related death, the causes of death in
our cohort closely paralleled those in the general population.
Table 4 presents the results of the Cox proportional
hazards model for eight patient attributes and exposures
listed in Tables 1 and 2 that were available for most patients
and were significantly associated with all-cause mortality,
after adjustment for age and sex. Supplementary Table S2
online provides these estimates including three potential
confounders for which data were unavailable for B15% of
patients. In our cohort, the significant risk factors for death are
similar to those for the general population including obesity,
smoking, being unmarried, having less education, fair or poor
health, hypertension, elevated uric acid, and white blood cell
count (Table 4).
Among the four quartiles of the extent of psoriasis at entry
(2–15%, 16–26%, 27–42%, and442% BSA), only patients in the
highest quartile (442% BSA on entry) had a significantly higher
risk of death (hazard ratio (HR)¼ 1.55, 95% CI¼1.23–1.93)
than those with the least psoriasis at entry. The mortality risk of
patients with intermediate extents of psoriasis was nearly
identical to those with less psoriasis (Table 4).
The results of the primary multivariate and all univariate
and multivariate sensitivity analyses demonstrated significant
associations between very severe psoriasis and all-cause
mortality and with deaths not due to CVD or cancer.
Although CVD was the most frequent cause of death in our
cohort, no significant relationship between increasing extent
of psoriasis and CVD mortality was seen in these analyses
(Tables 4 and 5, and Supplementary Tables S2 and S3 online).
Table 1. Attributes and exposures of PUVA study cohort
at entry to study in 1975–1976 for 1,376 of the 1,380
originally enrolled who survived to 1 January 1977
(N)
Gender
Male 891 (65%)
Female 485 (35%)
Education
Post high school/unknown 738 (53%)
High school or less 545 (40%)
Unknown 93 (7%)
Married
No 402 (30%)
Yes 971 (70%)
Unknown 3 (o1%)
Body mass index (kgm2)1,2
p302 975 (71%)
4302 204 (15%)
Unknown 197 (14%)
BSA (quartiles)3
BSA 2–15% 326 (26%)
BSA 16–26 322 (23%)
BSA 27–42 347 (25%)
BSA 442 349 (25%)
Unknown 32 (2%)
Blood pressure1
o135 and o95 983 (71%)
X135 or X95 104 (8%)
Unknown 289 (21%)
General health4
Fair or poor 210 (15%)
Good or excellent 1,153 (84%)
Unknown 13 (o1%)
Alcohol use1
No 230 (17%)
Yes 956 (69%)
Unknown 190 (14%)
Complete blood count (thousands)
o6.5 423 (31%)
6.5–8.1 480 (35%)
48.1 467 (34%)
Unknown 6
Uric acid (mg/dl)
Normal5 879 (64%)
High 462 (34%)
Unknown 35 (3%)
Abbreviations: BSA, body surface area; PUVA, oral psoralen and UVA
photochemotherapy.
1One center (184 patients) did not collect these data.
2Body mass index formula: weight (kg)/[(height (m))2; p30: normal weight,
430: obese.
3Body surface area estimation by dermatologist.
4Self-assessed general health at entry to clinical trial.
5For males, 3.4–7.0 and for females, 2.4–11.0 (mg/dl).
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Cardiovascular death
A total of 246 deaths due to CVD occurred in our cohort,
compared with the 241 expected (SMR¼1.02, 95%
CI¼0.90–1.16). The SMRs for subsets of CVD, including
myocardial infarction (ICD-9 (International Classification
of Disease, 9th Edition) code 410; SMR¼0.95, 95% CI¼
0.76–1.23) and all heart diseases (ICD-9 codes 390–398, 402,
404, 410, and 429; SMR¼1.03, 95% CI¼ 0.92–1.21), did
not suggest that severe psoriasis is associated with CVD
mortality. The well-established cardiovascular risk factors
were also significantly related to cardiovascular mortality in
our cohort (Table 4). In both the univariate and multivariate
analyses, patients in the highest quartile of extent of psoriasis
(442%) were at slightly but not statistically significantly
higher risk of dying from CVD than those in the lowest
quartile. No apparent difference in the risk of death because
of CVD was observed among the first three quartiles of
psoriasis severity (Table 4). Multivariate models showed
similar associations (Table 5 and Supplementary Table S2
online). The cohort’s proportional mortality odds ratio for
CVD standardized for age and gender equaled 0.40 versus
0.44 for the US white population (P¼ 0.08).
Cancer mortality
Observed cancer deaths were nearly identical to that
expected (SMR¼1.02, 95% CI¼ 0.86–1.20). Among the
potential confounders evaluated, only smoking and metho-
trexate use were significant predictors of death from cancer
(Table 4). In the univariate analysis, for those with greatest
extent of psoriasis, the risk of cancer wasB50% higher than
those with least extensive disease, but did not reach statistical
significance (Table 4). In the multivariate models, the HR for
cancer death among cohort members with 442% BSA was
lower, as expected, compared with those with o15% BSA
and also not significant (HR¼1.31, 95% CI¼ 0.90–1.92)
(Table 5 and Supplementary Table S2 online).
Other causes of death
Patients in our cohort were significantly more likely to die
from causes other than CVD and cancer (SMR¼ 1.39, 95%
CI¼1.22–1.59). The univariate, multivariate, and sensitivity
analyses, all indicate that very severe psoriasis (442% BSA)
was associated with an increased risk of death from causes
other than CVD and cancer compared with those with less
extensive psoriasis (Tables 4 and 5 and Supplementary Table
S2 online).
CVD versus other causes of death
In both univariate and multivariate stratified analyses, the
point estimate of the risk of death because of causes other
than CVD and cancer in the patients with most extensive
psoriasis compared with that observed for CVD was 41 but
did not reach statistical significance (multivariate estimate
HR¼ 1.27, 95% CI¼ 0.86–1.99).
DISCUSSION
Studies from specialized populations, including the General
Practice Research Database of outpatient records of British
Table 2. Patient exposures that were documented at
multiple interviews and may have changed over time
(N=30,817 patient-years of follow-up)
No. of follow-up years
Smoking more than the mean1
Yes 9,354 (30%)
No 19,916 (65%)
Unknown 1,547 (5%)
PUVA dosage more than mean2
Yes 11,699 (38%)
No 19,118 (62%)
MTX months more than mean3
Yes 7,610 (24%)
No 23,207 (76%)
Abbreviations: MTX, methotrexate; PUVA, oral psoralen and UVA
photochermotherapy.
1We calculated the mean total pack-years of smoking for all smokers in
the calendar year and compared it with the individual patient’s total
that year.
2We calculated mean total PUVA treatments for each year for the group
and compared it with the individual patient’s total that year.
3For MTX users, we calculated mean total MTX in use months for each
year for the group and compared it with the individual patient’s total that
year.
Table 3. Observed and expected deaths, SMR, and
95% CI by cause of death and extent of psoriasis
among 1,376 cohort patients
Observed
(N) Expected
SMR
(95% CI)
Underlying cause of death
All causes 617 560.28 1.11 (1.02–1.20)
Major cardiovascular
diseases1
246 241.2 1.02 (0.90–1.16)
Neoplasms2 146 143.4 1.02 (0.86–1.20)
Other causes3 225 161.4 1.39 (1.22–1.59)
Percent psoriasis at entry (quartiles)
o16 137 140.6 0.97 (0.82–1.15)
16–26 137 135.9 1.01 (0.85–1.19)
27–42 138 135.2 1.02 (0.86–1.21)
442 190 123.4 1.54 (1.33–1.77)
Missing 15 10.7 1.40 (0.78–2.31)
Abbreviations: CI, confidence interval; SMR, standard mortality ratio.
1International Classification of Disease, 9th Edition (ICD-9)-codes:
390–434, 436–448.
2ICD-9 codes: 140–208.
3Includes 19 patients for whom we could not establish the cause of
death.
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Table 4. Cox proportional HRs with 95% CIs for PUVA cohort for death by cause and by patient attributes and
exposures—adjusted for sex and age
Cause of death
All deaths (N=617) Cardiovascular deaths (N=246) Cancer (N=146) All other deaths (N=225)
Attribute/exposure HR, 95% CI HR, 95% CI HR, 95% CI HR, 95% CI
Percent psoriasis (quartiles)
o15 1 1 1 1
16–26 1.04 (0.82–1.31) 1.05 (0.73–1.53) 0.99 (0.61–1.63) 1.07 (0.71–1.58)
27–42 1.03 (0.81–1.30) 1.00 (0.69–1.45) 1.09 (0.67–1.76) 1.02 (0.68–1.58)
43–100 1.55 (1.23–1.93) 1.37 (0.97–1.94) 1.49 (0.94–2.36) 1.79 (1.24–2.59)
Body mass index (kgm–2)
p30 1 1 1 1
X30 1.27 (1.03–1.57) 1.27 (0.90–1.78) 1.43 (0.95–2.15) 1.18 (0.84–1.68)
Education
Post high school 1 1 1 1
High school or less 1.38 (1.17–1.64) 1.41 (1.09–1.85) 1.40 (1.00–1.97) 1.34 (1.00–1.78)
Married
No 1 1 1 1
Yes 0.70 (0.58–0.83) 0.70 (0.52–0.93) 0.83 (0.57–1.21) 0.62 (0.46–0.83)
Blood pressure
o95 and o135 1 1 1 1
X95 or X135 1.45 (1.13–1.86) 1.69 (1.15–2.49) 1.27 (0.75–2.14) 1.39 (0.91–2.12)
General health
Good or excellent 1 1 1 1
Fair or poor 1.96 (1.64–2.42) 2.46 (1.84–3.27) 1.08 (0.66–1.77) 2.08 (1.51–2.86)
Alcohol
No 1 1 1 1
Yes 0.81 (0.65–1.00) 0.79 (0.56–1.11) 0.81 (0.52–1.26) 0.82 (0.58–1.18)
Smoking
No or less than mean pack-years 1 1 1 1
Yes and more than mean pack-years 1.43 (1.20–1.69) 1.35 (1.03–1.77) 1.67 (1.17–2.38) 1.39 (1.05–1.85)
PUVA treatments
Less than mean number 1 1 1 1
Greater than mean number 0.81 (0.68–0.96) 0.74 (0.56–0.97) 0.98 (0.69–1.37) 0.80 (0.60–1.06)
Methotrexate use, months
None or less than mean 1 1 1 1
Greater or equal to mean 1.14 (0.95–1.36) 0.97 (0.72–1.31) 1.41 (0.99–2.00) 1.17 (0.87–1.57)
White blood cell count (thousands)
o6.5 1 1 1 1
6.5–8.1 1.27 (1.04–1.57) 1.00 (0.73–1.37) 1.89 (1.22–2.92) 1.32 (0.91–1.89)
48.1 1.72 (1.40–2.11) 1.29 (0.94–1.75) 1.90 (1.21–2.99) 2.25 (1.61–3.17)
Uric acid (mg/dl)
Normal 1 1 1 1
High 1.43 (1.21–1.67) 1.41 (1.09–1.81) 1.55 (1.11–2.15) 1.37 (1.04–1.79)
Abbreviations: CI, confidence interval; HR, hazard ratio; PUVA, oral psoralen and UVA photochermotherapy.
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general practitioners, have suggested that patients with severe
psoriasis have increased risks of CVD that are independent of
usual cardiovascular risk factors and attributable to their
psoriasis (Rocha-Pereira et al., 2001; Reynoso-von Drateln
et al., 2003; Gelfand et al., 2006, 2007; Melerba et al., 2006;
Neimann et al., 2006; Akhyani et al., 2007; Huerta et al.,
2007; Ludwig et al., 2007; Shapiro et al., 2007; Wakkee
et al., 2007; Gerdes et al., 2008; Kaye et al., 2008; Kimball
et al., 2008a, b; Ohtsuka, 2008; Balci et al., 2009). Some
have suggested that the increased risk of CVD observed in
patients with severe psoriasis may be a result of cutaneous
inflammation and immunologic alterations common to
psoriasis and CVD (Sterry et al., 2007; Fridewald et al.,
2008; Spa¨h, 2008; Federman et al., 2009; Kimball et al.,
2008a, b). Proponents of this view had stated that ‘‘in
particular it is important to determine the impact of clinical
markers of psoriasis, such as body surface area, on the risks of
MI in patients with psoriasis’’ (Gelfand et al., 2006). An
association between psoriasis severity and C-reactive protein
levels, a modest risk factor for CVD, has been observed
(Strober et al., 2008). A clinical trial to test the hypothesis that
tumor necrosis factor-a blocker will ‘‘decrease the risk of
heart disease’’ is underway (ClinicalTrials.gov).
In our 30-year prospective study of a cohort of US
patients with severe psoriasis, mortality rates were slightly
and significantly higher than those for the comparable
US population of whom substantially B0.1% have psoriasis
of comparable severity (Stern et al., 2004). When deaths
due to liver disease are excluded, mortality in the cohort
was nearly identical to that expected (SMR¼1.06, 95%
CI¼0.97–1.15).
In our cohort, patients with exceptionally severe psoriasis
(442% BSA) have significantly higher overall mortality rates
than cohort patients with less extensive but still severe
psoriasis as well as that observed in the general population.
However, our data do not support the hypothesis that either
severe psoriasis or greater extent of psoriasis is a unique or
significant independent risk factor for death due to CVD.
Our prospective study included severely affected patients
enrolled at 16 university centers nationwide in the first large
clinical trial of a widely heralded new therapy for psoriasis
(Parrish et al., 1974). The only health-related exclusions to
entry were pregnancy and inability to stand for 20minutes
(Melski et al., 1977; Stern et al., 1984). However, the
robustness of our findings that compare cause-specific
mortality in our cohort with that expected for a comparable
US population depend on our study having limited
selection bias.
A well cohort effect (i.e., selection bias) could account for
our failure to find an increased risk of CVD deaths in the
cohort overall, but our data suggest that this is unlikely. At
enrollment, 15% of our cohort assessed their health as fair or
poor, significantly higher than the 11% reporting fair or poor
health in a comparable population (Hendershot, 1988, 2006).
At enrollment, 29% of the cohort had hypertension and 15%
had body mass index 430 kgm–2; age-adjusted prevalence
consistent with those for the general population (NCHSa).
A comparison of the population-based First National
Health and Nutrition Examination Survey (NHANES-1)
cohort and ours also argues against our observation reflecting
a well cohort effect. The average age of whites in NHANES-1
was slightly older than our population (50 vs. 46) (McGee
et al., 1996). The proportion of patients in the PUVA cohort
with white blood cell counts in the highest tercile for
NHANES was similar to that observed in the NHANES cohort
(Gillum et al., 2005). Abnormal uric acid levels were more
frequent in our cohort than in the NHANES cohort (Fang and
Alderman, 2000). The increases in risk for both all-cause
mortality and cardiovascular mortality associated with
elevated white blood cell count and uric acid that we
observed were similar to those seen in NHANES-1 (Fang and
Alderman, 2000; Gillum et al., 2005). Including these
biological variables in our multivariate models further
reduced the risk associated with very severe psoriasis.
Our cohort enrolled residents of many states. However,
death rates for the states that accounted for most patients are
Table 5. Multivariate HR with 95% CI estimates for PUVA cohort by cause of death1 and percent psoriasis
Cause of death
All deaths (N=577)2 Cardiovascular deaths (N=209)2 Cancer deaths (N=133)2 Other (N=188)2
HR, 95% CI HR, 95% CI HR, 95% CI HR, 95% CI
Percent psoriasis (quartiles)
o15 1 1 1 1
16–26 1.04 (0.82–1.32) 1.01 (0.69–1.49) 1.01 (0.62–1.67) 0.93 (0.60–1.43)
27–42 1.04 (0.82–1.32) 1.00 (0.68–1.48) 1.00 (0.61–1.63) 0.97 (0.63–1.49)
43–100 1.45 (1.16–1.82) 1.23 (0.85–1.80) 1.32 (0.82–2.14) 1.57 (1.01–2.26)
Highest quartile versus all less severe 1.42 (1.18–1.69) 1.22 (0.89–1.66) 1.31 (0.90–1.92) 1.56 (1.14–2.13)
Abbreviations: CI, confidence interval; HR, hazard ratio; PUVA, oral psoralen and UVA photochermotherapy.
1Adjusted for all significant potential confounders except obesity, alcohol, and blood pressure, which in bivariate analysis altered HR by o10% (see
Materials and Methods). Potential confounders included in model by cause of death: all deaths: uric acid; cardiovascular deaths: education, general health,
PUVA, and uric acid; cancer deaths: education and methotrexate; other causes: education, general health, smoking, and uric acid.
2Number of deaths included in the multivariate model (see Table 4 for total deaths by cause).
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B4% lower than national averages. Therefore, our estimates
of SMRs may be slight underestimates. However, the
differences between the national death rates we utilized
and state-specific rates would not impact our findings
concerning the relation of increasingly severe psoriasis and
mortality. The direction and magnitude of risks associated
with potential confounders we observed are generally similar
to those observed in the general population (Fang and
Alderman, 2000; Gillum et al., 2005; Fiscella and Tancredi,
2008). If present, the effect of selection bias with respect to
CVD would be expected to decrease over time, which would
be reflected in a higher SMR for CVD in the later years of the
study that was not seen (P¼0.52).
All members of our cohort had severe psoriasis based on
clinical or General Practice Research Database criteria (Stern
et al., 2004; Gelfand et al., 2006; Leonardi et al., 2008). More
than half of our cohort has used methotrexate. The cohort has
had 4450,000 UVB and 200,000 PUVA treatments.
For each end point, univariate and multivariate statistical
models, including those of our sensitivity analyses, yielded
highly consistent results. Cohort members with the most
extensive psoriasis (top quartile) are significantly more likely
to die than those with less psoriasis overall and from causes
other than CVD and cancer.
Our study has a number of strengths and limitations. It was
prospective and achieved a high rate of follow-up. It enrolled
a geographically dispersed cohort with severe psoriasis and
did not exclude patients because of ill health or medication
use. Based on death certificates and other medical informa-
tion, we used standard methods to assess the cause of death.
Hence, our classification of the cause of death should be
comparable with that used in calculating the population
incidence data. Death records are likely to be more specific
than outpatient records used in other studies of CVD in
psoriasis (Gelfand et al., 2006; Hammad et al., 2008). With
430,000 person-years of prospective, we only have suffi-
cient power to assess frequent causes of death.
Our findings demonstrate that exceptionally extensive
psoriasis and/or its treatment are associated with increased
mortality from noncardiovascular causes. Our findings
strongly argue against a substantial or greater association of
severe and extremely severe psoriasis with CVD than with
other causes of death. The high prevalence of risk factors for
CVD in patients with severe psoriasis and the nearly
significant increased risk of CVD mortality in people with
exceptionally severe psoriasis suggest that clinicians screen
patients with severe psoriasis for CVD risk factors and be sure
that psoriasis patients with risk factors receive appropriate
counseling and treatment.
MATERIALS AND METHODS
Study population
In 1975–1976, 16 dermatology departments at university centers
established the Clinical Cooperative Trial of Oral Methoxsalen
Therapy (PUVA) to evaluate a new and highly promising therapy for
psoriasis (Melski et al., 1977). The eligibility criteria were severe
psoriasis and the ability to stand for 20minutes and not be pregnant.
At enrollment, a detailed questionnaire and laboratory and physical
examinations established medical history and physical attributes
including some risk factors for CVD.
In the late 1976, a long-term follow-up study was organized
enrolling 1,380 of the 1,450 participants in the clinical trial. They
form the PUVA Follow-Up Study cohort. Its methods have been
detailed previously (Stern et al., 1984, 1997). Follow-up information
gathered on the cohort included that from 22 cycles of follow-up
interviews, 9 cycles of dermatologic examinations, as well as
medical records and death certificates. To decrease lead time bias,
this report is restricted to 1,376 of the 1,380 cohort patients
who survived to 1 January 1977 and were prospectively followed
until 2005.
Our study conformed to the Declaration of Helsinki Principles.
The study was approved by the BIDMC Committee on Clinical
Investigation (IRB). Written informed consent was obtained at entry
to the original study (1975–1976) and at enrollment in the follow-up
study (1976).
Ascertainment and classification of mortality
From enrollment to 2004, trained interviewers performed 22 cycles
of telephone interviews that documented patient’s health status. If
patients could not be reached, clinicians and patient-designated
relatives and friends were contacted. We attempted to obtain death
certificate information for all those reported dead or we could not
contact. We also utilized the NDI, a nationwide database that
ascertains cause of death for 99% of US residents (NCHSb; NDI,
2005). We used the same methods to determine the cause of death
as are used to calculate US mortality rates (NCHSc, d). After 1998,
death certificates utilized the tenth revision of the ICD codes.
Therefore, we converted these codes to ICD-9 codes using the ICD
code translator (TDRdata.com) to determine the cause of death.
Two physicians evaluated all deaths with any ambiguity
concerning the proper application of coding rules to determine the
cause of death. For 41 of 96 such cases, full agreement about correct
code was reached. For 47 cases, ambiguity between two diagnoses
persisted. For 19 of these 47 cases, we coded CVD as the underlying
cause of death. For 17 of these 19 cases, diabetes mellitus was an
alternative. For only 6 of the 28 remaining cases, CVD could be
considered a likely cause of death.
To test for consistency between our coding of underlying cause of
death and the official NDI coding, which is used to calculate cause-
specific death rates, we compared the causes of death in nearly 60%
sample of deaths available as a complete file of NDI codes. In this
sample, our coding agreed with the NDI in 490% of cases and the
total number of deaths coded as CVD differed by o2%.
We used diagnosis, gender, age, and calendar-year-specific death
rates for whites to calculate the expected number of deaths (CDCa;
Doody et al., 2001; NCHSe, f). We did this for deaths overall, for all
diagnostic (three-digit) categories with X4 observed deaths, and
NCHS (National Center for Health Statistics)-defined groupings for
CVD and cancer (CDCb).
Statistical analysis
To evaluate our cohort’s overall and cause-specific mortality
experience, we compared the observed and expected numbers of
deaths. We calculated the expected number of deaths for all-cause
mortality and for specific diseases based on the United States.
We applied age (5-year intervals), sex, and calendar-year-
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specific mortality rates for whites from the NCHS Multiple-Cause
Mortality Files of the Centers for Disease Control and Prevention
(CDCa, b). For 1977–1978, we lacked detailed data, and used 1979
death rates for these years. Rates for 1979 differed by o2% from
1977–1978 rates. Based on Poisson distribution, we calculated the
SMR and its exact 95% CI for each cause of death in our cohort with
at least four deaths. All analyses were performed using statistical
software Stata Version 10 (StataCorp, College Station, TX).
Using percent BSA at entry to the study, as assessed by
specially trained dermatologists who categorized the percentage of
BSA covered with psoriasis for each of 33 body areas, we
stratified our population’s extent of psoriasis into quartiles.
At entry, the lowest quartile of patients had BSA 2–15%, BSA in
the second and third quartiles were 16–26% and 27–42%,
respectively. Those in the highest quartile had at least 43% BSA
involvement (Table 1).
To assess the association of increasingly severe psoriasis with the
risk of death, we used Cox proportional hazard models (Cleaves
et al., 2008). We graphed the hazard function over time for deaths
because of all causes as well as cardiovascular deaths and deaths
due to other causes separately. Visual inspection of the log(-log)
survival plots against time confirmed that the proportional hazard
assumption were met. We developed Cox regression models that
related psoriasis severity to mortality overall and separately for CVD,
cancer, and other causes (see Supplementary Table S1 online for
classification of ICD-9 codes included in each category). We
estimated the HR for psoriasis severity and potential confounders
(see Tables 1 and 2) to each end point. Following recent STROBE
(strengthening the reporting of observational studies in epidemio-
logy) recommendations, we tested all potential confounders that
were significant at Po0.1 in the univariate analysis and did bivariate
analyses of each of these variables with psoriasis severity (Von Elm
et al., 2007). In our primary multivariate models, any potential
confounder that altered the point estimate of the HR for the most severe
quartile of psoriasis byX7% (e.g., from 1.5 to p1.45 orX1.55) were
included. All models included age and sex. For 8 of the 11 potential
confounding variables, data were available for 495% of patients (see
Tables 1 and 2). One center with 184 patients did not provide blood
pressure, alcohol use, and body mass index data. Therefore, these
variables were excluded from the primary multivariate models. The
results of multivariate analyses including these three variables are
presented in Supplementary Table S2 online. We used stratified Cox
regression to estimate differences in HRs for competing risk (CVD
versus other causes of death) (Lunn and McNeil, 1995).
We performed a number of sensitivity analyses. Using Cox
regression analysis, we developed a multivariate model that
included all potential confounders significantly related to each
outcome and with Po0.20 in the multivariate model that related
extent of psoriasis to risk of death by cause. We also used binomial
regression to determine the association of psoriasis severity and
death by cause. Our measures of risk in this model were age–gender,
cause, and year-specific death rates for whites in the United States.
These binomial regression models also included all significant
potential confounders with Po0.20 in the univariate analyses.
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